• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity
Clin Rev Allergy Immunol. 2023 Jun 20. doi: 10.1007/s12016-023-08963-3. Online ahead of print.ABSTRACTBefore becoming a cornerstone in the treatment of numerous immune-mediated diseases, mycophenolate mofetil (MMF) was first introduced as an immunosuppressive agent in transplant immunology and later received the attention of rheumatologists and clinicians involved in the management of autoimmune diseases. MMF is now a widespread immunosuppressive drug for the treatment of several conditions, including lupus nephritis, interstitial lung disease associated with systemic sclerosis, and anti-neutrophil cytoplasm antibody (ANCA...
Source: Clinical Lung Cancer - June 20, 2023 Category: Cancer & Oncology Authors: Rithika Bhat Antonio Tonutti Suraj Timilsina Carlo Selmi M Eric Gershwin Source Type: research

Is your kid actin out? A series of six patients with inherited ARPC1B deficiency and review of the literature
CONCLUSION: ARPC1B deficiency has a variable and heterogeneous clinical spectrum, expanded by these cases to include keloid scars and Epstein-Barr virus chronic hepatitis. A novel deletion in exon 8 is shared by three unrelated families and might be the result of a founder effect.PMID:36708766 | DOI:10.1016/j.jaip.2022.12.045
Source: Clinical Lung Cancer - January 28, 2023 Category: Cancer & Oncology Authors: Estefan ía Vásquez-Echeverri Marco Antonio Yamazaki-Nakashimada Edna Venegas Montoya Selma Cecilia Scheffler Mendoza Lina Maria Castano-Jaramillo Edgar Alejandro Medina-Torres Maria Edith Gonz ález-Serrano Melissa Espinosa-Navarro Juan Carlos Bustamant Source Type: research

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research

Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - April 29, 2019 Category: Cancer & Oncology Source Type: research

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies
Abstract Due to the increase in utilization of chemotherapies and antibodies, drug hypersensitivity reactions have increased dramatically worldwide, preventing the use of first-line therapies and impacting patients’ survival and quality of life. Some of the more frequently used medications in cancer include taxanes for ovarian, lung, breast, and prostate cancers. Monoclonal antibodies are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-α, CD30, VEGF-A, IgE, ...
Source: Clinical Reviews in Allergy and Immunology - June 7, 2016 Category: Allergy & Immunology Source Type: research

Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies.
Abstract Due to the increase in utilization of chemotherapies and antibodies, drug hypersensitivity reactions have increased dramatically worldwide, preventing the use of first-line therapies and impacting patients' survival and quality of life. Some of the more frequently used medications in cancer include taxanes for ovarian, lung, breast, and prostate cancers. Monoclonal antibodies are used in the treatment of neoplastic, autoimmune, and inflammatory diseases, and their clinical applications are becoming broader. Monoclonal antibody targets include CD20, HER-2, EGFR, IL-6 receptor, TNF-α, CD30, VEGF-A, IgE, an...
Source: Clinical Colorectal Cancer - June 7, 2016 Category: Cancer & Oncology Authors: Bonamichi-Santos R, Castells M Tags: Clin Rev Allergy Immunol Source Type: research

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme
Conclusions The overall rates and types of malignancies observed in the tofacitinib clinical programme remained stable over time with increasing tofacitinib exposure.
Source: Annals of the Rheumatic Diseases - April 6, 2016 Category: Rheumatology Authors: Curtis, J. R., Lee, E. B., Kaplan, I. V., Kwok, K., Geier, J., Benda, B., Soma, K., Wang, L., Riese, R. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological Source Type: research

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Conclusions The addition of TNFi to sDMARD does not alter the risk of cancer in RA patients selected for TNFi in the UK.
Source: Annals of the Rheumatic Diseases - May 8, 2015 Category: Rheumatology Authors: Mercer, L. K., Lunt, M., Low, A. L. S., Dixon, W. G., Watson, K. D., Symmons, D. P. M., Hyrich, K. L., BSRBR Control Centre Consortium, Maiden, Price, Hopkinson, O'Reilly, Hordon, Griffiths, Porter, Madhok, Hassell, Cooper, Choy, Walsh, Emery, Knight, Bru Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis, Clinical diagnostic tests, Epidemiology Clinical and epidemiological research Source Type: research

Contamination prompts voluntary injectables recall
Mylan N.V. has announced a voluntary recall of specific lots of injectable products for conditions including rheumatoid arthritis, severe psoriasis, lung cancer, breast cancer, ovarian cancer, and acute nonlymphocytic leukemia because foreign particles were observed during testing of retention...
Source: Skin and Allergy News - April 25, 2015 Category: Dermatology Tags: IMN News RHEUM News RHEUM Rheumatoid Arthritis SAN Clinical News SAN News SAN Psoriasis FPN News Source Type: news